您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > IDE 1
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
IDE 1
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
IDE 1图片
CAS NO:1160927-48-9
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议

产品介绍
IDE 1 是定形内胚层 1 的诱导剂。
Cas No.1160927-48-9
化学名2-((E)-((Z)-(6-carboxy-1-hydroxyhexylidene)hydrazono)methyl)benzoic acid
Canonical SMILESO/C(CCCCCC(O)=O)=N\N=C([H])\C1=CC=CC=C1C(O)=O
分子式C15H18N2O5
分子量306.31
溶解度DMF: 30 mg/ml,DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml,DMSO: 25 mg/ml,Ethanol: 0.1 mg/ml
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

IDE1 is an inducer of definitive endoderm 1.

IDE1 enhances the definitive endoderm (DE) differentiation of human-induced pluripotent stem cells (hiPSCs) with Activin A/Wnt3a being significantly more potent in both 2D and 3D cultures compared to IDE1. IDE1 could efficiently induces DE differentiation through various protocols in vitro. Treatment of the hiPSCs-derived EBs with IDE-1 shows minor increase (p<0.01) of DE-markers cells compared to Activin A/Wnt3a treatment. IDE1 possess several advantages over other inducing factors including high permeability, influence, diversity, low cost, and easy to use and for the first time, Melton’s team showed that Activin A can be substituted by two cell-permeable small molecules, IDE1 and IDE2. IDE1 could induce phosphorylation of Smad2 after incubation for 24 h or more at levels comparable to those induced by Activin A treatment. Treatment of hiPSCs with IDE1 (2 mM) also leads to endodermal differentiation but with a significantly lower efficiency than Activin A/Wnt3a[1].

References:
[1]. Hoveizi E, et al. Definitive endoderm differentiation of human-induced pluripotent stem cells using signaling molecules and IDE1 in three-dimensional polymer scaffold. J Biomed Mater Res A. 2014 Nov;102(11):4027-36.